BDNF Gene Polymorphism and Antidepressant Response in Han Chinese Patients with First-Episode Late-Life Depression

Area of Science:

• Neuroscience
• Genetics
• Psychiatry

Background:

• Late-life depression (LLD) presents unique challenges in treatment response.
• Brain-derived neurotrophic factor (BDNF) plays a crucial role in neuronal plasticity and is implicated in depression.
• Investigating genetic factors like BDNF polymorphisms may offer insights into personalized antidepressant therapy.

Purpose of the Study:

• To examine the association between BDNF gene polymorphisms and antidepressant treatment efficacy in first-episode LLD patients.
• To explore the relationship between serum BDNF levels, neuropsychological status, and treatment outcomes.
• To identify predictors of antidepressant response in this specific patient population.

Main Methods:

• Recruited 72 patients with first-episode LLD, with 57 completing an 8-week antidepressant treatment course.
• Assessed depression severity (HAMD-17) and neuropsychological function (RBANS) at baseline and post-treatment.
• Measured serum BDNF levels and genotyped BDNF polymorphisms using ELISA and Agena® MassARRAY.

Main Results:

• Significant improvements in HAMD-17, RBANS scores, and serum BDNF levels were observed post-treatment.
• Male sex (OR=10.094) and BDNF gene polymorphism (OR=6.559) were identified as significant predictors of treatment efficacy.
• No significant differences in RBANS scores or serum BDNF levels were found between effective and ineffective treatment groups.

Conclusions:

• Antidepressant treatment impacts serum BDNF levels in LLD patients.
• Male patients with the Val/Val BDNF genotype may exhibit a better response to conventional antidepressants.
• Findings suggest BDNF gene polymorphisms could be potential biomarkers for predicting LLD treatment outcomes, though larger studies are needed.